Engineered MSCs Break Endothelial‐Myofibroblast Crosstalk in Pulmonary Fibrosis: Reconstructing the Vascular Niche
Advanced Materials · 2025
DOI: 10.1002/adma.202414601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Yue-Fei Fang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Mesenchymal Stem Cells, Myofibroblasts, Endothelial Cells. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Key R&D Program of China, Leading technology foundation research project of Jiangsu Province, Haihe Laboratory of Cell Ecosystem Innovation Fund.
Abstract (Originalsprache)
In the progress of pulmonary fibrosis (PF), the normal vascular niche plays a crucial role in alveolar regeneration by secreting angiocrine factors. However, the malignant interaction between myofibroblasts and vascular endothelial cells results in significant loss of pulmonary capillaries in fibroblast foci, which promotes continuous deterioration of fibrosis. Herein, an engineered mesenchymal stem cell (MSC) therapeutic named MSC‐MM@LPHN is developed for reconstructing the vascular niche, which is formed by modifying the surface of MSC with ROS‐responsive lipid polymeric hybrid nanoparticles encapsulating the metformin and macitentan. Due to the homing ability of MSC, the MSC‐MM@LPHN can effectively target lung tissue, then induce myofibroblast dedifferentiation to reduce the secretion of cytokines that cause endothelial cell damage and preventing endothelial cells from turning into a fibrotic phenotype, leading to recovery of the vascular endothelial cells function. Combined with the role of MSC‐secreted growth factors promoting angiogenesis, the MSC‐MM@LPHN ultimately constructs normal vascular structure in the fibroblast area and reverses bleomycin‐induced PF. The findings suggest targeting the cell network in the vascular niche can effectively treat PF, which provides a novel therapeutic strategy for fibrosis‐related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing, 210009, China.
- Jiangsu Renocell Biotech Co., Ltd, Nanjing, 211100, China.
- Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, 16419, South Korea.
- Key Laboratory of Drug Metabolism and Pharmacokinetics, Haihe Laboratory of Cell Ecosystem, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
- College of Pharmacy, Yanbian University, Yanji, 133002, China.
ORCID-Profile: Hu-Lin Jiang
Förderung
- National Key R&D Program of China
- Leading technology foundation research project of Jiangsu Province
- Haihe Laboratory of Cell Ecosystem Innovation Fund
- Nanjing Scientific and Technological Special Project for Life and Health
- Jilin Provincial Foundation of Changbai Talent Outstanding Team
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Project of State Key Laboratory of Natural Medicines
- China Pharmaceutical University
Zitieren
APA
Fang, Y. F., Zhang, C., Han, M. M., Wang, Y., Zhou, T. J., Xing, L., Wei, N., Wang, J., Jeong, J. H., Zhou, F., Wang, G. J., & Jiang, H. L. (2025). Engineered MSCs Break Endothelial‐Myofibroblast Crosstalk in Pulmonary Fibrosis: Reconstructing the Vascular Niche. Advanced Materials. https://doi.org/10.1002/adma.202414601
Vancouver
Fang YF, Zhang C, Han MM, Wang Y, Zhou TJ, Xing L, et al. Engineered MSCs Break Endothelial‐Myofibroblast Crosstalk in Pulmonary Fibrosis: Reconstructing the Vascular Niche. Advanced Materials. 2025. doi:10.1002/adma.202414601
BibTeX
@article{Fang2025,
author = {Fang, Yue-Fei and Zhang, Chen and Han, Meng-Meng and Wang, Yi and Zhou, Tian-Jiao and Xing, Lei and Wei, Ning and Wang, Jing and Jeong, Jee-Heon and Zhou, Fang and Wang, Guang-Ji and Jiang, Hu-Lin},
title = {Engineered MSCs Break Endothelial‐Myofibroblast Crosstalk in Pulmonary Fibrosis: Reconstructing the Vascular Niche},
journal = {Advanced Materials},
year = {2025},
doi = {10.1002/adma.202414601}
}
EUVIMED